HRP20220228T1 - Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom - Google Patents

Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom Download PDF

Info

Publication number
HRP20220228T1
HRP20220228T1 HRP20220228TT HRP20220228T HRP20220228T1 HR P20220228 T1 HRP20220228 T1 HR P20220228T1 HR P20220228T T HRP20220228T T HR P20220228TT HR P20220228 T HRP20220228 T HR P20220228T HR P20220228 T1 HRP20220228 T1 HR P20220228T1
Authority
HR
Croatia
Prior art keywords
lymphoma
combination
use according
hodgkin
antibody
Prior art date
Application number
HRP20220228TT
Other languages
English (en)
Croatian (hr)
Inventor
Jutta AMERSDORFFER
Stefan Steidl
Mark Winderlich
Susanne KROHN
Lisa Rojkjaer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HRP20220228T1 publication Critical patent/HRP20220228T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HRP20220228TT 2011-08-16 2012-08-14 Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom HRP20220228T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US201261654097P 2012-06-01 2012-06-01
EP12747923.6A EP2744515B1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti-cd19 antibody and a nitrogen mustard
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (1)

Publication Number Publication Date
HRP20220228T1 true HRP20220228T1 (hr) 2022-05-13

Family

ID=47714801

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220228TT HRP20220228T1 (hr) 2011-08-16 2012-08-14 Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom

Country Status (24)

Country Link
US (3) US20140255427A1 (https=)
EP (2) EP2744515B1 (https=)
JP (1) JP6184952B2 (https=)
KR (3) KR20200058583A (https=)
CN (1) CN103732252B (https=)
AU (1) AU2012296907B2 (https=)
BR (1) BR112013033919B1 (https=)
CA (2) CA2841875C (https=)
CY (1) CY1125122T1 (https=)
DK (1) DK2744515T3 (https=)
ES (1) ES2909722T3 (https=)
HR (1) HRP20220228T1 (https=)
HU (1) HUE058350T2 (https=)
IL (1) IL230293B (https=)
LT (1) LT2744515T (https=)
MX (1) MX354479B (https=)
PL (1) PL2744515T3 (https=)
PT (1) PT2744515T (https=)
RS (1) RS63238B1 (https=)
RU (1) RU2625222C2 (https=)
SG (1) SG10201606785UA (https=)
SI (1) SI2744515T1 (https=)
SM (1) SMT202200159T1 (https=)
WO (1) WO2013024097A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519757A (ja) * 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
SMT202100541T1 (it) * 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
RS62155B1 (sr) * 2016-05-30 2021-08-31 Morphosys Ag Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
HRP20231229T1 (hr) * 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
TW202334231A (zh) * 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CZ302070B6 (cs) * 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
JP2008519047A (ja) 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
KR20110111303A (ko) * 2009-01-16 2011-10-10 글락소스미스클라인 엘엘씨 벤다무스틴 및 항-ｃｄ２０ 항체의 조합을 이용한 암의 치료
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
KR20120054069A (ko) * 2009-08-14 2012-05-29 로슈 글리카트 아게 플루다라빈 및/또는 미토잔트론과 어푸코실화된 ｃｄ20 항체의 복합 요법
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
US20240366756A1 (en) 2024-11-07
MX2013014933A (es) 2014-04-16
RU2014103492A (ru) 2015-09-27
EP2744515B1 (en) 2022-02-09
EP4062936A1 (en) 2022-09-28
AU2012296907B2 (en) 2017-01-05
KR20140064873A (ko) 2014-05-28
CY1125122T1 (el) 2024-12-13
SG10201606785UA (en) 2016-10-28
US20200353077A1 (en) 2020-11-12
PT2744515T (pt) 2022-05-19
SI2744515T1 (sl) 2022-05-31
IL230293B (en) 2019-01-31
JP6184952B2 (ja) 2017-08-23
NZ617770A (en) 2016-01-29
JP2014525926A (ja) 2014-10-02
SMT202200159T1 (it) 2022-05-12
DK2744515T3 (da) 2022-03-28
KR102115203B1 (ko) 2020-05-28
CA2841875A1 (en) 2013-02-21
KR20200058583A (ko) 2020-05-27
CN103732252B (zh) 2017-11-10
CA2841875C (en) 2021-11-02
WO2013024097A1 (en) 2013-02-21
CA3137321A1 (en) 2013-02-21
CN103732252A (zh) 2014-04-16
PL2744515T3 (pl) 2022-05-30
MX354479B (es) 2018-03-07
HUE058350T2 (hu) 2022-07-28
KR20190107749A (ko) 2019-09-20
BR112013033919B1 (pt) 2022-11-16
EP2744515A1 (en) 2014-06-25
ES2909722T3 (es) 2022-05-10
LT2744515T (lt) 2022-04-25
BR112013033919A2 (pt) 2017-12-19
RU2625222C2 (ru) 2017-07-12
RS63238B1 (sr) 2022-06-30
US20140255427A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
HRP20220228T1 (hr) Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
HRP20220224T1 (hr) Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
HRP20192100T1 (hr) Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe
CL2022000328A1 (es) Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017)
HRP20211291T1 (hr) Kombinacije i njihove primjene
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
GT201500105A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
CY1121646T1 (el) Παραγωγα μορφινανης για την αγωγη υπερβολικης δοσης ναρκωτικων
EP4353747A3 (en) Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
ECSP11011403A (es) Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
HRP20210838T1 (hr) Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe
MX392618B (es) Un anticuerpo monoclonal de anti-beta7 para usarse en el tratamiento de un trastorno inflamatorio gastrointestinal.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
CL2013003298A1 (es) Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
RU2015134422A (ru) Применение левоцитиризина и монтелукаста при лечении васкулита
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση
WO2017181099A8 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith